OncoMatch/Clinical Trials/NCT03198546
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Is NCT03198546 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GPC3 and/or TGFβ targeting CAR-T cells for hepatocellular carcinoma.
Treatment: GPC3 and/or TGFβ targeting CAR-T cells — The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3/TGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/TGFβ-CAR-T cell immunotherapy on human will firstly be tested.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: GPC3 overexpression (protein expression)
patients with advanced HCC,which express GPC3 protein
Prior therapy
Cannot have received: gene therapy
Had accepted gene therapy before
Lab requirements
Kidney function
adequate kidney function
Liver function
child-pugh-turcotte score <7
Cardiac function
adequate heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify